Cross-Sector entity
All 1 tracked stories fall under one category: pharma. Cidara Therapeutics is most often covered alongside Centers for Disease Control and Prevention, which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention Cidara Therapeutics, all published on February 27, 2026.
1 verified story tracked
Last mentioned: Feb 27, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Cidara Therapeutics is most often covered alongside Centers for Disease Control and Prevention, which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention Cidara Therapeutics, all published on February 27, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cidara Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
New York health authorities have issued a high-level alert regarding the accelerated spread of a deadly, drug-resistant fungal pathogen across healthcare facilities. The pathogen, identified as Candida auris, poses a severe threat to immunocompromised patients and highlights a critical gap in the current antifungal pharmaceutical pipeline.
